Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Qiagen N : fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

share with twitter share with LinkedIn share with facebook
09/17/2020 | 05:06pm EDT

  • Transaction strengthens QIAGEN’s leadership position in automated molecular testing
  • QIAGEN acquires remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million
  • Medium- and high-throughput NeuMoDx automation solutions based on PCR testing technology to now be integrated into QIAGEN’s portfolio on a global basis
  • Menu of test solutions for infectious diseases – which already includes COVID-19 – to be expanded, especially in the U.S.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology.

The transaction was completed after QIAGEN received U.S. regulatory clearance for the full acquisition. In 2018, QIAGEN had purchased a 19.9% stake in NeuMoDx along with the right to acquire the remaining NeuMoDx stake at a price of $234 million. The final payment price for this remaining stake includes customary purchase price adjustments for cash, indebtedness and transaction costs. Also as part of the 2018 agreement, QIAGEN has distributed the high-throughput NeuMoDx™ 288 and the medium-throughput NeuMoDx™ 96 platforms in Europe and other markets outside the U.S.

“NeuMoDx’s automated molecular testing platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics assays, including laboratory-developed tests,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “NeuMoDx has built an unparalleled platform that has demonstrated superior value during the coronavirus pandemic. This will expand QIAGEN’s portfolio of automated testing solutions and provide another driver for future growth.”

“NeuMoDx devices offer labs with medium to high throughput exactly what they need,” Bernard added. “Labs want compact systems with true random access, fast turnaround time, full automation and comprehensive menus. The full integration of the NeuMoDx systems will allow QIAGEN to address laboratory needs in almost any setting for molecular diagnostics. We are excited to be able to build on NeuMoDx’s success and will jointly work on expanding our product portfolio and global distribution.”

Please find the full press release here

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about QIAGEN N.V.
04:15pQIAGEN N : expands its existing Epigenomic offering in the United States with Sa..
10/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
10/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
10/28QIAGEN NV : JP Morgan maintains a Buy rating
10/28QIAGEN N : launches QIAseq Human Exome TR Insights, a new integrated solution fo..
10/28QIAGEN NV : Jefferies reiterates its Neutral rating
10/27QIAGEN : 3Q Earnings Snapshot
10/27QIAGEN N.V. : to hold investor call on Wednesday, October 28, after releasing re..
10/27QIAGEN N : Ad hoc Announcement according to Art. 17 Market Abuse Regulation
10/27QIAGEN N : reports strong results for third quarter and first nine months of 202..
More news
Financials (USD)
Sales 2020 1 818 M - -
Net income 2020 277 M - -
Net Debt 2020 996 M - -
P/E ratio 2020 41,8x
Yield 2020 -
Capitalization 11 138 M 11 138 M -
EV / Sales 2020 6,67x
EV / Sales 2021 5,76x
Nbr of Employees 5 300
Free-Float 92,9%
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 55,82 $
Last Close Price 47,60 $
Spread / Highest target 38,7%
Spread / Average Target 17,3%
Spread / Lowest Target -20,2%
EPS Revisions
Thierry Bernard Chief Executive Officer
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.44.05%11 138
LONZA GROUP AG57.42%45 407
SEAGEN INC.70.53%33 903
CELLTRION, INC.39.78%28 585
MODERNA, INC.236.09%25 940